Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed AML
NCT07743112Phase 2Recruiting
- Sponsor
- Guangzhou Zaiji Medical Technology
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nefextinib in acute myeloid leukemia (AML), sponsored by Guangzhou Zaiji Medical Technology. Primary endpoints: Dose-Limiting Toxicity at 6 months, Adverse Events at 24 months and 2 more. Started Sep 2025; status: recruiting.
02
Drugs
nefextinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07743112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07743112.